

Pharmacokinetics of Injectable Meloxicam and Buprenorphine in the Naked Mole-Rat (*Heterocephalus glaber*)

Caileen R. Moran, Thomas J. Park, Rochelle Buffenstein, Sayan Chakrabarty, Matthew O. Lindeblad, Jeffrey D. Fortman, Cynthia R. Adams

Institutional affiliation of each author –

Caileen R. Moran: Post-doctoral Training Program, University of Illinois Chicago, Chicago, Illinois

Thomas J. Park: Department of Biological Sciences, University of Illinois Chicago, Chicago, Illinois

Rochelle Buffenstein: Department of Biological Sciences, University of Illinois Chicago, Chicago, Illinois

Sayan Chakrabarty: Department of Statistics, University of Illinois Urbana-Champaign, Champaign, Illinois

Matthew O. Lindeblad: Department of Pharmacology and Regenerative Medicine, Toxicology Research

Laboratory, University of Illinois Chicago, Chicago, Illinois

Jeffrey D. Fortman: Biologic Resources Laboratory, University of Illinois Chicago, Chicago, Illinois

Cynthia R. Adams: Biologic Resources Laboratory, University of Illinois Chicago, Chicago, Illinois

**Corresponding author. Email : (cmoran3@uic.edu)*

Running Title – Pharmacokinetics of Meloxicam and Buprenorphine in the Naked Mole-Rat

Abstract

Unique characteristics of the naked mole-rat (NMR) have made it increasingly popular as a laboratory animal model. These rodents are used to study many fields of research including longevity and aging, cancer, circadian rhythm, pain, and metabolism. Currently, the analgesic dosing regimens used in the NMR mirror those used in other rodent species. However, there is no pharmacokinetic (PK) data supporting the use of injectable analgesics in the NMR. Therefore, we conducted two independent PK studies to evaluate two commonly used analgesics in the NMR; meloxicam (2 mg/kg SC) and buprenorphine (0.1 mg/kg SC). In each study, blood was collected at 8 time points after subcutaneous injection of meloxicam or buprenorphine (0 (pre-dose), 0.25, 0.5, 1, 2, 4, 8, and 24 hrs). Three NMRs were used per time point for a total of 24 animals per PK study. Plasma concentrations of meloxicam were highest between 0.5 hrs and 1 hr post-injection. Levels remained above the extrapolated dog and cat therapeutic threshold levels (390-911 ng/mL) for at least 24 hrs. Plasma concentrations of buprenorphine were highest between 0.25 and 0.5 hrs post-injection. Levels remained above the human therapeutic threshold (1 ng/mL) for up to 21 hrs. No skin reactions were seen in association with injection of either drug. In summary, this data supports dosing meloxicam (2 mg/kg SC) once every 24 hrs and buprenorphine (0.1 mg/kg SC) once every 8-12 hrs in the NMR. Further studies should be performed to evaluate the clinical efficacy of these drugs by correlating plasma concentrations with post-operative pain assessments.

Abbreviations and Acronyms: Naked mole-rat, NMR

Introduction

One of the most important aspects of laboratory animal medicine is the management of pain and distress. The *Guide for the Care and Use of Laboratory Animals (Guide)*, Public Health Service (PHS) Policy, and Animal Welfare Act all include statements mandating that pain and distress experienced by research animals be minimized where possible.¹⁻³ Providing appropriate

pain management to laboratory animals is not only required by law but is also one of the core ethical obligations addressed in the 3Rs principle, which is used as a guiding foundation for improving laboratory animal welfare throughout the world.^{30; 39} Furthermore, it has been established that pain and suffering can dramatically alter an animal's behavior, physiology, and immunology; therein creating unpredictable, significant variables that can impair scientific quality, reliability, and reproducibility.^{6; 32; 44} Taken together, these reasons make providing appropriate analgesia intrinsic to the framework of humane and efficacious animal research.

Non-steroidal anti-inflammatory drugs (NSAIDs) are a category of analgesics that are commonly used to treat mild to moderate pain in veterinary medicine. NSAIDs work through the inhibition of cyclooxygenase (COX) enzymes. COX-1 enzymes are present in many tissues throughout the body and generally mediate homeostatic functions such as maintaining the integrity of the gastric mucosa, preserving normal platelet function, and regulating renal blood flow. COX-2 enzymes are activated in damaged or inflamed tissues and generally amplify the inflammatory response which includes pain, inflammation, and fever. Overall, the analgesic, anti-inflammatory, and antipyretic effects of NSAIDs predominantly result from COX-2 inhibition, and the negative side effects such as gastrointestinal toxicity, coagulopathy, and renal and hepatic failure largely result from COX-1 inhibition. Meloxicam is a NSAID that preferentially inhibits COX-2 over COX-1, and therefore it has a decreased risk of negative side effects compared to other, non-selective NSAIDs.^{17; 19; 23; 49} Pharmacokinetic (PK) and efficacy studies have proven meloxicam to be an effective analgesic in the mouse, rat, and many other species used in research.^{11; 24; 31; 34; 50} Based on these studies, commonly used doses for meloxicam include 2-10 mg/kg SC every 8-12 hrs in mice and 1 mg/kg SC every 12-24 hrs in rats.^{8; 11; 20; 34; 40}

Opioids are a category of analgesics that are commonly used to treat moderate to severe pain in veterinary medicine. Opioids work by mimicking the effects of endogenous opioids and acting as an agonist, antagonist, and/or partial agonist on the μ , δ , and κ opioid receptors. The principal positive effect of opioid use is analgesia, while negative side effects can include respiratory depression, hypothermia, constipation, nausea, and addiction. Opioids can produce variable amounts of both analgesia and negative side effects depending on their action on and affinity to the different opioid receptors. Buprenorphine is a synthetic opiate classified as a partial μ receptor agonist and κ receptor antagonist that provides analgesia with minimal respiratory depression.^{14; 35; 43} PK and efficacy studies have proven buprenorphine to be an effective analgesic in the mouse, rat, and many other species used in research.^{13; 21; 28; 35; 38} Based on these studies, commonly used doses for buprenorphine include 0.1-0.5 mg/kg every 4-6 hrs in the mouse and 0.05-0.1 mg/kg every 6-8 hrs in the rat.^{8; 20; 34; 40}

Naked mole-rats (NMRs) (*Heterocephalus glaber*) are an emerging non-traditional laboratory animal model that are used in many fields of research including longevity and aging, cancer, circadian rhythm, pain, and metabolism.^{9; 10; 16; 18; 41; 45} As the use of NMRs in research has increased, there is a need to establish data that can guide the medical management of pain in this unique species. PK studies are conducted to determine the absorption, distribution, metabolism, and elimination of test compounds in a living organism. Mathematical models derived from these data allow for the characterization of drug disposition, half-life, elimination constants, and exposure levels.^{27; 46 48; 51} Ultimately, PK studies support our understanding of how different compounds are processed by the body in different species. Currently, analgesic practices used for the NMR mirror those used in other rodent species such as mice and rats, for which there is well established PK data. Differences in the metabolic activity of the NMR as

compared to other mammals has been described in literature, and this may have an effect on drug absorption and kinetics in this species.^{18; 26; 42} To date, no PK profiles exist for either meloxicam or buprenorphine in the NMR.

The aim of the project was to perform two PK studies in the NMR to assess two commonly used analgesics in rodents, injectable meloxicam and buprenorphine. Our hypothesis is that when NMRs are given a dose of meloxicam that is consistent with the current mouse and rat dosing practices (2 mg/kg SC)^{8; 11; 20; 34; 40}, plasma concentrations of this drug will remain above the proposed therapeutic plasma concentration that has been shown to be effective in dogs and cats, 390-911 ng/mL, for 12-24h.^{20; 24; 31} We also hypothesize that when NMRs are given a dose of buprenorphine that is consistent with the current mouse and rat dosing practices (0.1 mg/kg SC)^{4; 15; 20; 21; 25; 36}, plasma concentrations of this drug will remain above the proposed therapeutic plasma concentration that is effective in other species, 1 ng/mL, for 6-8h.^{13; 21; 28; 34} The results of this study will ultimately contribute valuable information to support our understanding of pain management in this unique species with the ultimate goal of improving animal welfare.

Materials and Methods – Insert Below

Ethics Statement

All procedures were performed under approval from the University of Illinois Chicago Animal Care Committee. All animals were housed in accordance with the *Guide*, PHS Policy, and Animal Welfare Act and Regulations in an AAALAC-accredited facility.¹⁻³

Animals

Experiments were conducted on clinically normal NMRs (*Heterocephalus glaber*, n = 48, age = >1 year, weight = 20-70g). NMRs were housed under semi-natural conditions in an artificial burrow system consisting of standard mouse and/or rat microisolator cages interconnected with PVC pipe. These systems were lined with cellulose bedding (Envigo 7070C Certified Diamond Dry Bedding®) and maintained within an animal housing room on a 14:10h light: dark cycle at 80 +/- 2°F and 30–70% relative humidity.⁵ NMRs were fed a diet consisting primarily of sweet potato/yam and a rotating mix of other seasonal fruits and vegetables. No water was provided as NMRs obtain all their water from their food.⁴⁷ All NMRs used in this study were obtained from an existing in-house colony.

Pharmacokinetic Study - Groups

NMRs were divided into 2 groups, one meloxicam group and one buprenorphine group. In each group, samples were collected at 8 time points post-administration: 0 (pre-dose), 0.25, 0.5, 1, 2, 4, 8, and 24 hrs. Three animals were used per time point for both meloxicam and buprenorphine PK analysis, for a total of 48 study animals. The number of time points and animals per time point were chosen with direct input and guidance from an experienced scientist in the field of PK analysis.

Pharmacokinetic Study - Compound Administration

Meloxicam (Meloxicam Injectable Solution, 5mg/mL, 20 mL/vial, Packager: LLC dba COVETRUS NORTH AMERICA, NDC: 11695-6936-2) was diluted with sterile water to a final dose concentration of 0.5 mg/mL used in this study. Buprenorphine (Buprenorphine HCL Injection, 0.3 mg/mL, 1 mL/vial, Packager: Par Pharmaceutical, Inc., NDC: 42023-179-05) was

diluted with sterile saline to a final dose concentration of 0.03 mg/mL used in this study. All animals were weighed immediately before compound administration to allow for accurate dosing of medications. The method of dosing was identical for both compounds. Subcutaneous (SC) injections were administered as a single bolus without anesthesia to manually restrained NMRs. A 23-25g needle was used depending on the size of the NMR. The area of skin on the dorsal surface of neck between the shoulders was pinched into a tent shape and the needle was inserted at the base of this skin tent. Needle positioning was confirmed by tugging slightly upward on the syringe and visualizing subcutaneous placement. The contents of the syringe were fully injected, and the needle was withdrawn. The area of the back where the injection was given was gently rubbed and the animal was returned to its cage. Meloxicam was given at a dose of 2 mg/kg once SC and buprenorphine was given at a dose of 0.1 mg/kg once SC. This injection was considered time point 0.

Pharmacokinetic Study - Sample Collection

Terminal caudal vena cava blood collection was performed under isoflurane anesthesia. After confirming anesthetic depth, a 1-2cm full thickness abdominal incision was made. A 25–27-gauge needle was used to collect blood from the caudal vena cava, after which, blood was immediately transferred to a K2EDTA tube. Blood collection was completed in approximately 3 min and was directly followed by cardiac perfusion for collection of tissues for another study.

Pharmacokinetic Study – Plasma Sample Analysis

Prior to study initiation, 5 mLs (2.5 mLs/assay) of baseline NMR plasma in EDTA tubes was sent to the University of Tennessee College of Veterinary Medicine to calibrate the meloxicam and buprenorphine assays needed for PK analysis. This 5 mL volume was obtained from an existing flash-frozen plasma bank maintained by another PI at the author's institution. All blood samples from the study were collected in EDTA tubes and centrifuged for 10 min at 1025 x g. Plasma was stored in a -80°C freezer until it was sent on dry ice to the University of Tennessee College of Veterinary Medicine for PK analysis.

The analysis of meloxicam in plasma samples was conducted using reversed phase high performance liquid chromatography (HPLC) method with UV detection. The compounds were separated on a Xbridge C18 (4.6 x 250 mm, 5µm) column with a mobile phase of 10ml of glacial acetic acid in 1L of H₂O (pH 3.0 adjusted with sodium hydroxide) and acetonitrile (50:50). Absorbance was measured at 360 nm with a flow rate of 1 ml/min. Meloxicam was extracted from plasma samples using a liquid-liquid extraction. One hundred microliters of plasma was transferred to a screw top tube, and 15 µl of piroxicam (internal standard, 5 µg/mL) was added followed by 100 µl of 1 M HCL and 2 ml of chloroform. The tubes were vortexed for 60 seconds and then centrifuged for 20 min at 1070 x g. The organic phase was transferred to a glass tube and evaporated to dryness with nitrogen. Standard curves for plasma analysis were prepared by fortifying untreated plasma with meloxicam to produce a linear concentration range of 5 -15000 ng/ml. The intra- and inter-assay variability was less than 10% and the average recovery for meloxicam was 93%. The lower limit of quantification during validation was 5 ng/ml.

The analysis of buprenorphine in plasma was conducted using reverse phase HPLC and single-quadrupole mass spectrometry. The compounds were separated on a XBridge C18 (4.6 x 50 mm, 3.5 µm) column with mixture of water with 0.1% formic acid and acetonitrile with 0.1% formic

acid (90:10). The flow rate was 0.80 mL/min, and the column temperature were ambient which was 30°C. The compounds were detected by positive selected ion recording (SIR). The scan rate was 2 pts/s, gain 1, capillary voltage 0.8 kV, cone voltage 12, ion source temperature 150°C and probe temperature 600°C. Nitrogen was used as the nebulizing gas. Buprenorphine was detected at 468.32 m/z and fentanyl was detected at 337.34 m/z. Buprenorphine was extracted from plasma samples using a protein precipitation with 0.1 M zinc sulfate and acetonitrile. Plasma samples (100 µl) were transferred to a 7 ml glass screw top tube then 10 µl of internal standard (0.1 µg/ml fentanyl) added. Two milliliters of acetonitrile and 100 µL of ZnSO₄ were added and tubes were capped, vortexed for 30 s then centrifuged for 10 min at 1020 x g. The supernatant was removed and placed in a glass tube and evaporated to dryness with nitrogen gas. Samples were reconstituted in 200 µl of mobile phase and 55 µl injected into the HPLC system. Standard curves for plasma were prepared by spiking untreated plasma with buprenorphine which produced a linear concentration range of 0.1 to 25 ng/ml. Intra- and inter-assay was less than 10% and the average recovery of buprenorphine was 100%. The lower limit of quantification is 0.1 ng/ml.

Pharmacokinetic Study – Pharmacokinetic Analysis

The plasma concentration-time data following the single subcutaneous dose of either meloxicam (2 mg/kg) or buprenorphine (0.1 mg/kg) was analyzed by non-compartmental methods using R version 4.3.1. The package ‘ncappc’ was used for pharmacokinetic analysis. The nominal time of blood collection was used for the analysis. The non-compartmental analysis provided estimates of the following parameters for each drug in each group: terminal elimination rate constant (λ_z) and elimination half-life ($t_{1/2-\lambda_z}$), area under the plasma concentration-time curve from time 0 to the last observed concentration (AUC_{0-last}), area under the plasma concentration-time curve from time 0 to infinity ($AUC_{0-\infty}$), area under the plasma concentration-time moment curve from time 0 to the last observed concentration ($AUMC_{0-last}$), area under the plasma concentration-time moment curve from time 0 to infinity ($AUMC_{0-\infty}$), clearance (CL), volume of distribution (V_{λ_z}), maximum observed plasma concentration (C_{max}), the time (T_{max}) of observing C_{max} , the mean residence time from time 0 to last observable concentration (MRT_{0-last}), and the mean residence time from time 0 to infinity ($MRT_{0-\infty}$). The λ_z was estimated by linear regression of the terminal exponential portion of the log plasma concentration-time curve. At least 3 time points during a discernable terminal elimination phase and correlation coefficient for the log-linear regression analysis of > 0.80 were required for acceptance of the λ_z calculation. The $t_{1/2-\lambda_z}$ was determined by dividing 0.693 (ln 2) by λ_z . The linear trapezoidal method was used to calculate AUC_{0-last} and $AUMC_{0-last}$. Extrapolation to infinity was performed by dividing the last observed plasma concentration by λ_z . The $AUC_{0-\infty}$ and $AUMC_{0-\infty}$ were obtained as the summing the extrapolated area to AUC_{0-last} and $AUMC_{0-last}$, respectively. Clearance (CL) was calculated by dividing dose by $AUC_{0-\infty}$. The MRT_{0-last} and $MRT_{0-\infty}$ were estimated as the ratios of the corresponding area under the moment curve (AUMC) to AUC. The CL was divided by λ_z to estimate the volume of distribution (V_{λ_z}). We also reported the median values of the PK parameters along with their first and third quantiles of the 3 animals per group per drug. The interpolating line, the line between two time points t_1 and t_2 with mean plasma concentration y_1 and y_2 , was calculated using the formula: $y = y_1 + (t - t_1) \times (y_2 - y_1) / (t_2 - t_1)$.

Results

Both meloxicam and buprenorphine were administered to all NMRs ($n = 48$) successfully on the first attempt. Overall, no adverse effects such as injection site reactions^{24; 45}, changes in behavior, mentation, appetite, or activity were observed during the period between injection and sample collection in the NMRs.

Meloxicam (2 mg/kg SC) reached a $C_{\max}$ of 7705 ng/mL at a $T_{\max}$ of 0.5 hr post injection. The $t_{1/2-\lambda_z}$ of meloxicam was 7.1 hr and the $AUC_{0-\infty}$ was 78778.52 ng hr/mL. The elimination rate (λ_z) was 10%/hr and the CL from the plasma was 0.52 mL/hr (Table 1). The mean concentration curve exceeded the upper limit of the assumed therapeutic threshold (911 ng/ml) at 0.0381 hrs and the interpolated line did not fall below the lower limit of the threshold (390 ng/mL) within 24 hours (Figure 1).

Buprenorphine (0.1 mg/kg SC) reached a $C_{\max}$ of 15.27 ng/mL at a $T_{\max}$ of 0.5 hr post injection. The $t_{1/2\lambda_z}$ was 5.55 hr and the $AUC_{0-\infty}$ was 73.39 ng hr/mL. The λ_z of buprenorphine was 12%/hr and the CL from the plasma was 8348.07 mL/hr (Table 1). The mean concentration curve for buprenorphine exceeded the assumed therapeutic threshold (1 ng/ml) at 0.0279 hrs and the interpolated line fell below this threshold at 21.6703 hrs (Figure 2).

Discussion

Several testing methods can be used to help establish species-specific dosing regimens of drugs. These tests include PK studies, toxicity studies, analgesiometric tests, and postsurgical pain assessments. PK studies alone are not used to evaluate the clinical physiologic effects of drugs; however, they do provide critical data on how drugs are absorbed, metabolized, and excreted in different species. This data, when used in combination with other clinical testing modalities, is essential to the determination of safe and efficacious drug dosing regimens.

Two commonly used analgesics used in laboratory animal medicine are meloxicam and buprenorphine. Previous studies have evaluated the PK profiles and clinical efficacy of these analgesics in laboratory animal species, including the dog, cat, mouse, and rat, but none have been performed using the NMR. The aim of this study was to establish a PK profile for both meloxicam (2 mg/kg SC) and buprenorphine (0.1 mg/kg SC) in the NMR. Determining the clinical efficacy of meloxicam and buprenorphine in the NMR was not the intent of this study, however these doses have been used at our institution to clinically manage pain in this species.

Unique physiological differences between species can lead to significant effects on drug pharmacokinetics. This point is exemplified by the different clearance (CL) rates of meloxicam between mice, rats, and, as our study shows, NMRs. In a previous study, mice that received meloxicam (1.6 mg/kg SC) displayed a clearance of 155 mL/hr and rats receiving this same dose displayed a clearance of 15 mL/hr.^{11; 12} Our study used a slightly higher dose of meloxicam (2 mg/kg SC) and reported a clearance of 0.52 mL/hr in the NMR. Therefore, when comparing these studies, the CL of meloxicam in the mouse is approximately 10 times higher than the rat and approximately 300 times higher than the NMR. This is just one example of how a single pharmacokinetic variable can differ substantially between species. Therefore, it is considered best practice to perform species-specific pharmacokinetic studies even when using drugs, such as meloxicam and buprenorphine, that are well-established in our more commonly used research animals.

Important values obtained by PK studies include $C_{\max}$, $T_{\max}$, C_{last} , $t_{1/2\lambda_z}$, $AUC_{0-\infty}$, λ_z , and CL. $C_{\max}$ is the highest reported concentration of drug in the blood and $T_{\max}$ is the time at which $C_{\max}$ is achieved. The elimination half-life of a drug, or $t_{1/2\lambda_z}$, is the time at which the drug has lost half of its maximum concentration. $AUC_{0-\infty}$, or the area under the curve across time, represents the actual body exposure to a drug after administration of a dose of the drug, this is typically expressed in ng hr/mL. The elimination rate, or λ_z is the fraction of drug eliminated per hr. The C_{last} is the last quantifiable concentration of the drug and, in this study, corresponds with the drug concentration taken at 24 hrs. The interpolated line is calculated using the formula: $y = y_1 + (t - t_1) \times (y_2 - y_1) / (t_2 - t_1)$, where y equals the mean plasma concentration and t equals time. Using linear interpolation, plasma concentration at any time between two determined data points can be predicted and represented on a graph as a line connecting these data points. The therapeutic threshold is the minimum plasma concentration of drug required to provide effective analgesia and this value is determined by performing efficacy studies using defined doses. The amount of time that drug concentrations remain above the therapeutic threshold is called the therapeutic window, and this determines the duration of action (DOA) of the drug. Combining PK data and therapeutic threshold data helps support the determination of dosing regimens for appropriate analgesia.^{27; 48}

The targeted therapeutic plasma meloxicam concentration of 390-911 ng/mL has been established in cats and dogs, based on correlations between PK studies and clinical assessment of subjects.^{20; 24; 31} In this study, when NMRs were dosed at time point 0 with meloxicam (2 mg/kg), quantifiable plasma concentrations above the therapeutic threshold were achieved by the first blood sample collection at 0.25 hrs, and a $C_{\max}$ of 7705 ng/mL was reached at 0.5 hrs. This quick absorption time and time taken to reach $C_{\max}$ supports the use of meloxicam to treat urgent analgesic needs in the NMR. Most notably, the plasma concentration of meloxicam was maintained above the targeted therapeutic threshold through the 24 hr time point with levels never falling below the threshold at any time point. The final 24 hr time point reported a C_{last} of 753.58 ng/mL, which still fell within the upper range of the targeted therapeutic threshold for meloxicam. As no additional blood samples were collected after this final 24 hr time point, the exact DOA may be even longer than this duration. Overall, if the therapeutic threshold for meloxicam in the NMR is consistent with that of cats and dogs, then this data conservatively supports a dosing regimen of 2 mg/kg SC every 24 hrs in the NMR.

The targeted therapeutic plasma buprenorphine concentration of 1 ng/mL has been suggested in mice, rats, and humans, based on correlations between PK studies and clinical assessment of subjects.^{13; 21; 28; 34} In this study, when NMRs were dosed at time point 0 with buprenorphine (0.1 mg/kg), quantifiable plasma concentrations above the therapeutic threshold were achieved by the first blood sample collection at 0.25 hrs. In addition, when blood samples were collected at the 0.5 hrs time point, plasma concentrations of buprenorphine had already reached a $C_{\max}$ of 15.27 ng/mL. This quick absorption time and time taken to reach $C_{\max}$ supports the use of buprenorphine to treat urgent analgesic needs in the NMR. The plasma concentration of buprenorphine, as displayed by the interpolated line, was maintained above the targeted therapeutic threshold for at least 21 hrs. The C_{last} (0.54 ng/mL), taken at 24 hrs was below the targeted therapeutic threshold, but based on the values predicted by linear interpolation, a DOA of 21.6703 hrs was suggested. Assuming the therapeutic threshold for buprenorphine in the NMR is 1 ng/dL, then this data conservatively supports a dosing regimen of 0.1 mg/kg SC every 8-12 hrs in the NMR.

Overall, the results obtained from this study support giving meloxicam at a dose of 2 mg/kg SC every 24 hrs and buprenorphine at a dose of 0.1 mg/kg SC every 8-12 hrs in the NMR. To truly establish a dose recommendation, the therapeutic thresholds for both meloxicam and buprenorphine should be confirmed, and further studies should be performed to evaluate the clinical efficacy of these drugs by correlating plasma concentrations with analgesiometric tests or post-operative pain assessments in the NMR. Additionally, future studies should be performed to evaluate additional time points to better pinpoint the duration of action, and to further characterize factors such as toxicity, multiple consecutive dose administrations, long-term use, and sustained release formulation pharmacokinetics of both meloxicam and buprenorphine in the NMR.

Acknowledgements

The authors thank Sherry Cox and staff at the University of Tennessee College of Veterinary Medicine, Heather Charles (UIC), and Dr. Lorissa Lamoureux (UIC) for their assistance with this study.

References

References

1. **Animal Welfare Act as Amended.** 2023. 7 USC §2131–2156.
2. **Institute for Laboratory Animal Research.** 2011. Guide for the care and use of laboratory animals, 8th ed. Washington (DC): National Academies Press.
3. **Public Health Service.** 2015. Public health service policy on humane care and use of laboratory animals. U.S. Department of Health and Human Services, Washington, D.C. [2015 Reprint]
4. **Ageel AM.** 1986. Effects of desipramine and chlorimipramine on buprenorphine analgesia in mice. *Jpn J Pharmacol* **41**:139-145.
5. **Artwohl J, Hill T, Comer C, Park T.** 2002. Naked mole-rats: unique opportunities and husbandry challenges. *Lab Anim (NY)* **31**:32-36.
6. **Bailey J.** 2018. Does the stress of laboratory life and experimentation on animals adversely affect research data? A critical review. *Alternatives to laboratory animals: ATLA* **46**:291-305.
7. **Blankenship-Paris TL, Dutton JW, Goulding DR, McGee CA, Kissling GE, Myers PH.** 2016. Evaluation of buprenorphine hydrochloride Pluronic((R)) gel formulation in male C57BL/6NCrl mice. *Lab Anim (NY)* **45**:370-379.
8. **Bourque SL, Adams MA, Nakatsu K, Winterborn A.** 2010. Comparison of buprenorphine and meloxicam for postsurgical analgesia in rats: effects on body weight, locomotor activity, and hemodynamic parameters. *J Am Assoc Lab Anim Sci* **49**:617-622.
9. **Buffenstein R.** 2005. The naked mole-rat: a new long-living model for human aging research. *J Gerontol A Biol Sci Med Sci* **60**:1369-1377.
10. **Buffenstein R, Park T, Hanes M, Artwohl JE.** 2012. Chapter 45- Naked mole rat, pp. 1055-1071. In: Suckow MA, Stevens KA, Wilson RP editors. *The Laboratory Rabbit, Guinea Pig, Hamster, and Other Rodents*
11. **Busch U, Schmid J, Heinzel G, Schmaus H, Baierl J, Huber C, Roth W.** 1998. Pharmacokinetics of meloxicam in animals and the relevance to humans. *Drug Metabolism and Disposition* **26**:576-584.
12. **Chen PH, Boyd KL, Fickle EK, Locuson CW.** 2016. Subcutaneous meloxicam suspension pharmacokinetics in mice and dose considerations for postoperative analgesia. *J Vet Pharmacol Ther* **39**:356-362.
13. **Clark TS, Clark DD, Hoyt RF, Jr.** 2014. Pharmacokinetic comparison of sustained-release and standard buprenorphine in mice. *J Am Assoc Lab Anim Sci* **53**:387-391.
14. **Cohen B, Ruth LJ, Preuss CV.** 2023. Opioid analgesics. StatPearls. Treasure Island (FL): StatPearls Publishing.

15. **Cooper DM, Hoffman W, Wheat N, Lee HY.** 2005. Duration of effects on clinical parameters and referred hyperalgesia in rats after abdominal surgery and multiple doses of analgesic. *Comp Med* **55**:344-353.
16. **Edrey YH, Hanes M, Pinto M, Mele J, Buffenstein R.** 2011. Successful aging and sustained good health in the naked mole rat: a long-lived mammalian model for biogerontology and biomedical research. *Ilar J* **52**:41-53.
17. **Engelhardt G.** 1996. Pharmacology of meloxicam, a new non-steroidal anti-inflammatory drug with an improved safety profile through preferential inhibition of COX-2. *Br J Rheumatol* **35 Suppl 1**:4-12.
18. **Farhat E, Devereaux MEM, Pamentier ME, Weber JM.** 2020. Naked mole-rats suppress energy metabolism and modulate membrane cholesterol in chronic hypoxia. *Am J Physiol Regul Integr Comp Physiol* **319**:R148-r155.
19. **Fleischmann R, Iqbal I, Slobodin G.** 2002. Meloxicam. *Expert Opinion on Pharmacotherapy* **3**:1501-1512.
20. **Foley PL, Kendall LV, Turner PV.** 2019. Clinical management of pain in rodents. *Comparative Medicine* **69**:468-489.
21. **Foley PL, Liang H, Crichlow AR.** 2011. Evaluation of a sustained-release formulation of buprenorphine for analgesia in rats. *J Am Assoc Lab Anim Sci* **50**:198-204.
22. **Gades NM, Danneman PJ, Wixson SK, Tolley EA.** 2000. The magnitude and duration of the analgesic effect of morphine, butorphanol, and buprenorphine in rats and mice. *Contemp Top Lab Anim Sci* **39**:8-13.
23. **Ghlichloo I, Gerriets V.** Nonsteroidal anti-inflammatory drugs (NSAIDs). StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2023, StatPearls Publishing LLC.
24. **Giraudel JM, Diquelou A, Laroute V, Lees P, Toutain PL.** 2005. Pharmacokinetic/pharmacodynamic modelling of NSAIDs in a model of reversible inflammation in the cat. *Br J Pharmacol* **146**:642-653.
25. **Goldkuhl R, Jacobsen KR, Kalliokoski O, Hau J, Abelson KS.** 2010. Plasma concentrations of corticosterone and buprenorphine in rats subjected to jugular vein catheterization. *Lab Anim* **44**:337-343.
26. **Goldman BD, Goldman SL, Lanz T, Magaurin A, Maurice A.** 1999. Factors influencing metabolic rate in naked mole-rats (*Heterocephalus glaber*). *Physiol Behav* **66**:447-459.
27. **Grogan S, Preuss CV.** Pharmacokinetics. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2023, StatPearls Publishing LLC.
28. **Guarnieri M, Brayton C, Detolla L, Forbes-Mcbean N, Sarabia-Estrada R, Zadnik P.** 2012. Safety and efficacy of buprenorphine for analgesia in laboratory mice and rats. *Lab Animal* **41**:337-343.
29. **Hovard A, Teilmann A, Hau J, Abelson K.** 2015. The applicability of a gel delivery system for self-administration of buprenorphine to laboratory mice. *Lab Anim* **49**:40-45.
30. **Hubrecht RC, Carter E.** 2019. The 3Rs and Humane Experimental Technique: Implementing Change. *Animals (Basel)* **9**.
31. **Jeunesse EC, Bargues IA, Toutain CE, Lacroix MZ, Letellier IM, Giraudel JM, Toutain PL.** 2011. Paw inflammation model in dogs for preclinical pharmacokinetic/pharmacodynamic investigations of nonsteroidal anti-inflammatory drugs. *J Pharmacol Exp Ther* **338**:548-558.
32. **Jirkof P.** 2017. Side effects of pain and analgesia in animal experimentation. *Lab Animal* **46**:123-128.
33. **Jirkof P, Tourvieille A, Cinelli P, Arras M.** 2015. Buprenorphine for pain relief in mice: repeated injections vs sustained-release depot formulation. *Laboratory Animals* **49**:177-187.
34. **Kendall LV, Hansen RJ, Dorsey K, Kang S, Lunghofer PJ, Gustafson DL.** 2014. Pharmacokinetics of sustained-release analgesics in mice. *J Am Assoc Lab Anim Sci* **53**:478-484.
35. **Kendall LV, Oliver VL, Adamson TW.** 2023. Chapter 7 - Pharmacology of analgesics. In: Dyson MC, Jirkof P, Lofgren J, Nunamaker EA, Pang D, editors. *Anesthesia and analgesia in laboratory animals*, 3rd ed. San Diego (CA): Academic Press.
36. **Kögel B, Christoph T, Strassburger W, Friderichs E.** 2005. Interaction of mu-opioid receptor agonists and antagonists with the analgesic effect of buprenorphine in mice. *Eur J Pain* **9**:599-611.
37. **Kolesnikov YA, Wilson RS, Pasternak GW.** 2003. The synergistic analgesic interactions between hydrocodone and ibuprofen. *Anesth Analg* **97**:1721-1723.
38. **Myers PH, Goulding DR, Wiltshire RA, McGee CA, Dickerson AB, Comins MM, Shi M, Kissling GE, Lih FB, Deterding LJ, Laber-Laird KE, Blankenship-Paris TL.** 2021. Serum buprenorphine concentrations and behavioral activity in mice after a single subcutaneous injection of simbadol, buprenorphine SR-LAB, or standard buprenorphine. *Journal of the American Association for Laboratory Animal Science* **60**:661-666.

39. **NC3Rs.** [Internet]. 2018. The 3Rs. [Cited 22 August 2023]. Available at: <https://www.nc3rs.org.uk/who-we-are/3rs#what-are-the-3rs?>
40. **Nunamaker EA, Goldman JL, Adams CR, Fortman JD.** 2018. Evaluation of analgesic efficacy of meloxicam and 2 formulations of buprenorphine after laparotomy in female sprague–dawley rats. *Journal of the American Association for Laboratory Animal Science* **57**:498-507.
41. **Park TJ, Lu Y, Jüttner R, Smith ESJ, Hu J, Brand A, Wetzel C, Milenkovic N, Erdmann B, Heppenstall PA, Laurito CE, Wilson SP, Lewin GR.** 2008. Selective inflammatory pain insensitivity in the African naked mole-rat (*Heterocephalus glaber*). *PLoS Biology* **6**:e13.
42. **Park TJ, Reznick J, Peterson BL, Blass G, Omerbašić D, Bennett NC, Kuich PHJL, Zasada C, Browe BM, Hamann W, Applegate DT, Radke MH, Kosten T, Lutermann H, Gavaghan V, Eigenbrod O, Bégay V, Amoroso VG, Govind V, Minshall RD, Smith ESJ, Larson J, Gotthardt M, Kempa S, Lewin GR.** 2017. Fructose-driven glycolysis supports anoxia resistance in the naked mole-rat. *Science* **356**:307-311.
43. **Pathan H, Williams J.** 2012. Basic opioid pharmacology: an update. *Br J Pain* **6**:11-16.
44. **Poole T.** 1997. Happy animals make good science. *Laboratory Animals* **31**:116-124.
45. **Riccio AP, Goldman BD.** 2000. Circadian rhythms of locomotor activity in naked mole-rats (*Heterocephalus glaber*). *Physiol Behav* **71**:1-13.
46. **Slørdal L, Spigset O.** 2005. [Basic pharmacokinetics--absorption]. *Tidsskr Nor Lægeforen* **125**:886-887.
47. **Smith M, Buffenstein R.** 2021. Managed care of naked mole-rats. *Adv Exp Med Biol* **1319**:381-407.
48. **Starkey ES, Sammons HM.** 2015. Practical pharmacokinetics: what do you really need to know? *Arch Dis Child Educ Pract Ed* **100**:37-43.
49. **Van Hecken A, Schwartz JL, Depré M, De Lepeleire I, Dallob A, Tanaka W, Wynants K, Buntinx A, Arnout J, Wong PH, Ebel DL, Gertz BJ, De Schepper PJ.** 2000. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. *J Clin Pharmacol* **40**:1109-1120.
50. **Wright TL, Eshar D, McCullough C, Warner M, Kukanich B.** 2017. Pharmacokinetics of single-dose subcutaneous meloxicam injections in black-tailed prairie dogs (*Cynomys ludovicianus*). *J Am Assoc Lab Anim Sci* **56**:539-543.
51. **Zhivkova ZD, Mandova T, Doytchinova I.** 2015. Quantitative structure – pharmacokinetics relationships analysis of basic drugs: volume of distribution. *Journal of Pharmacy & Pharmaceutical Sciences* **18**:515.

Figure Legends

Figure 1. Plasma concentrations of meloxicam in NMRs after subcutaneous administration of a single dose (2 mg/kg). Black dots represent data points, and the black line connecting these dots represents the values calculated by linear interpolation. The red horizontal line represents the higher therapeutic threshold, and the black horizontal line represents the lower therapeutic threshold. The assumed therapeutic threshold range: 390-911 ng/ml. The horizontal blue lines represent the estimated duration of action of the drug, respective to the higher and lower threshold limits.





Figure 2. Plasma concentrations of buprenorphine in NMRs after subcutaneous administration of a single dose (0.1 mg/kg). Black dots represent data points, and the black line connecting these dots represents the values calculated by linear interpolation. The red horizontal line represents the assumed therapeutic threshold (1ng/ml). The horizontal blue line represents the estimated duration of action of the drug.



Tables

Table 1. Pharmacokinetic parameters of meloxicam (2 mg/kg) and buprenorphine (0.1 mg/kg) given subcutaneously to NMRs.

PK Parameter	Meloxicam (Median (IQR))	Buprenorphine (Median (IQR))
$C_{\max}$ (ng/ml)	7705 (7435.9-7989.26)	15.27 (15.14-18.35)
$T_{\max}$ (hr)	0.5 (0.5-0.75)	0.5 (0.38-0.5)
C_{last} (ng/ml)	753.58 (727.17-996.29)	0.54 (0.43-0.74)
T_{last} (hr)	24 (24-24)	24 (24-24)
$AUC_{0-\text{last}}$ (ng/ml hr)	62942.75 (62364.53-67273.94)	61.29 (60.51-79.02)
$AUC_{0-\infty}$ (ng/ml hr)	78778.52 (74694.66-79309.11)	73.39 (69.48-86.08)
AUC % extrapolated	10.86 (9.98-16.74)	6.53 (4.28-12.57)
$AUMC_{0-\text{last}}$ (ng/ml)	499040.51 (483678.36-541387.1)	477.43 (425.63-545.21)
$AUMC_{0-\infty}$ (ng/ml)	829326.88 (779851.18-1012351.96)	673.79 (592.32-838.13)
$MRT_{0-\text{last}}$ (hr)	8.08 (7.76-8.11)	6.34 (6.22-7.16)
$MRT_{0-\infty}$ (hr)	10.53 (10.44-12.75)	7.79 (7.31-10.73)
Rs_q	0.96 (0.87-0.97)	0.98 (0.96-0.98)
Corr	-0.98 (-0.99--0.93)	-0.99 (-0.99--0.98)
λ_z (/hr)	0.1 (0.08-0.1)	0.12 (0.1-0.14)
$t_{1/2\lambda_z}$ (hr)	7.1 (7.07-8.6)	5.55 (4.92-7.78)
Volume (ml)	7.56 (6.43-82.59)	51745.39 (28273.56-118221.68)
CL (ml/hr)	0.52 (0.52-8)	8348.07 (4474.09-10566.47)